8-K
filed May 18, 2023, 7:59 PM ET
CIK 0001102942
leadership
confidence high
sentiment neutral
materiality 0.60
InnovaQor CEO exits; Darrell Peterson named Interim CEO; new preferred stock issuance
InnovaQor, Inc.
- CEO Sharon Hollis departed May 14; Darrell Peterson appointed Interim President/CEO at $10,000/month salary.
- Board expanded to 4; Gerard Dab elected Chairman/Secretary; Francisco Roca III and Peterson join board.
- Company sold 300 shares of Series D Preferred Stock to three insiders for $30,000 total proceeds.
- Series D carries monthly dividends based on gross sales thresholds (5% above $500k, 10% above $1M, 2.5% above $2M).
- Series D ranks senior to common but junior to existing Series A-1, B-1, C-1 preferred; not convertible.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Darrell Peterson was elected as Director at InnovaQor, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
elected Darrell Peterson as a director to fill the vacancy
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Francisco Roca III was elected as Director at InnovaQor, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
Francisco Roca, III
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gerard Dab was elected as Chairman of the Board and Secretary at InnovaQor, Inc..
- Action
- elected
- Role
- Chairman of the Board and Secretary
Exact text from the filing
elected Gerad Dab as Chairman of the Board and Secretary of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Sharon Hollis departed as Director at InnovaQor, Inc..
- Role
- Director
Exact text from the filing
Prior to the written consent by Epizon Limited, the members of the Board of Directors were Gerard Dab, Justin Doherty and Sharon Hollis.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Darrell Peterson was named as Interim President and Chief Executive Officer at InnovaQor, Inc..
- Action
- named
- Role
- Interim President and Chief Executive Officer
Exact text from the filing
named Mr. Peterson to be Interim President and Chief Executive Officer of the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
InnovaQor, Inc.: Filed Certificate of Designation to authorize issuance of up to 500 shares of Series D Preferred Stock (effective 2023-05-12).
- Change
- charter amendment
- Effective
- 2023-05-12
Exact text from the filing
On May 12, 2023, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada to authorize the issuance of up to 500 shares of Series D Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
InnovaQor, Inc. entered into Securities Purchase Agreements with Alcimede Limited, Pathlogic Limited, and Hollis Capital Holdings, LLC valued at Total proceeds of $30,000 for the issuance of 100 shares of Series D Non-Convertible Preferred Stock (effective 2023-05-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Alcimede Limited, Pathlogic Limited, and Hollis Capital Holdings, LLC
- Value
- Total proceeds of $30,000 for the issuance of 100 shares of Series D Non-Convertible Preferred Stock
- Effective
- 2023-05-12
Exact text from the filing
On May 12, 2023, Rennova Health, Inc. (the “Company”) entered into Securities Purchase Agreements, dated as of May 12, 2023 (the “Purchase Agreements”), with Alcimede Limited (“Alcimede”), Pathlogic Limited (“Pathlogic”) and Hollis Capital Holdings, LLC (“Hollis Capital”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.